Taxon Therapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins for rare autoimmune diseases with unmet need.The company's product, TAX-01, is designed for the treatment of adults with autoimmune hemolytic anemia, a severe and rare blood disorder that occurs when antibodies directed against the person's own red blood cells cause them to burst, leading to an insufficient number of oxygen-carrying red blood cells in circulation.